NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · IEX Real-Time Price · USD
1.106
+0.246 (28.60%)
At close: Apr 19, 2024, 4:00 PM
1.180
+0.074 (6.69%)
After-hours: Apr 19, 2024, 7:59 PM EDT
Company Description
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.
It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.
The company was founded in 2017 and is based in Santa Ana, California.
NKGen Biotech, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Paul Y. Song M.D. |
Contact Details
Address: 3001 Daimler St, Santa Ana, California 92705 United States | |
| Phone | (949) 396-6830 |
| Website | grafacq.com |
Stock Details
| Ticker Symbol | NKGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845459 |
| ISIN Number | US65488A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Y. Song M.D. | Chief Executive Officer and Chairman |
| Sangwoo Park | Executive Director |
| James A. Graf | Interim Chief Financial Officer |
| Pierre Gagnon | Chief Operating Officer |
| Yoonmi Kang | Vice President of Technical Operations |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer |
| Denise A. Chua CLS, MBA, MT (ASCP) | Vice President of Investor Relations and Corporate Communications |
| Irene Chang | Vice President of Human Resources |
| Ryan Park C.F.A. | SVice President of Financial Planning and Analysis and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |